2015 ASCO Annual Meeting: New Data in 10 Different Cancers from Merck’s Rapidly Expanding Immuno-Oncology Research Program for KEYTRUDA® (pembrolizumab) to be Presented
Dateline City:
KENILWORTH, N.J.
New Findings Show Anti-tumor Activity of KEYTRUDA in Five Additional Cancers: Colorectal, Esophageal, Ovarian, Renal Cell Carcinoma and Small-Cell Lung Cancer
First-Time Presentations of DNA Mismatch Repair Deficiency Data in Colorectal and other Cancers and Nanostring RNA Data in Melanoma, Head and Neck and Gastric Cancers
Industry-leading Number of PD-1 Clinical Trials Resulting in Growing Body of Data for KEYTRUDA across 13 Tumor Types
KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that new investigational data in 10 different types of
cancer from the company’s immuno-oncology development program evaluating
its anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), will be
presented at the 51st Annual Meeting of the American Society
of Clinical Oncology (ASCO) in Chicago, May 29 – June 2, 2015.
Language:
English
Contact:
MerckMedia:Pamela Eisele, 267-305-3558Claire Mulhearn, 908-236-1118orInvestors:Joseph Romanelli, 908-740-1986Justin Holko, 908-740-1879
Ticker Slug: ...
Source: Merck.com - Corporate News - Category: Pharmaceuticals Tags: Oncology Newsroom Corporate News Latest News Source Type: news
More News: Cancer | Cancer & Oncology | Carcinoma | Clinical Trials | Colorectal Cancer | Esophagus Cancer | Gastric (Stomach) Cancer | Gastroenterology | Gastroschisis Repair | Head and Neck Cancer | Kidney Cancer | Lung Cancer | Melanoma | Merck | Nanotechnology | Ovarian Cancer | Ovaries | Pharmaceuticals | Renal Cell Carcinoma | Skin Cancer